As an example, we and others demonstrated that Mcl-1 over-expression confers resistance to ABT-737 and its down-regulation increases ABT-737 lethality in human leukemia cells and CLL [23, 30–32]. This evidence concerns the gene MCL1 and B-cell chronic lymphocytic leukemia.